This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Papageorgiou, A. Articles by McConkey, D. J. Search for Related Content PubMed PubMed Citation Articles by Papageorgiou, A. Articles by McConkey, D. J.

Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Interferon-Induced Apoptosis in Human Bladder Cancer Cells

Departments of ¹ Cancer Biology, ² Genitourinary Medical Oncology, and ³ Urology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Immunomodulators such as Bacillus Calmette-Guerin and interferon are clinically active in transitional cell carcinoma of the bladder, but their mechanisms of action remain unclear. Here we investigated the effects of IFN on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and apoptosis in a panel of 20 human bladder cancer cell lines. Six (30%) displayed significant DNA fragmentation in response to increasing concentrations of IFN (10–100,000 units/mL). In these lines IFN induced early activation of caspase-8, and DNA fragmentation was blocked by a caspase-8-selective inhibitor (IETDfmk), consistent with the involvement of death receptor(s) in cell death. IFN stimulated marked increases in TRAIL mRNA and protein in the majority of IFN-sensitive and IFN-resistant cell lines. A blocking anti-TRAIL antibody significantly inhibited IFN-induced DNA fragmentation in four of six IFN-sensitive cell lines, confirming that TRAIL played a direct role in cell death. Bortezomib (PS-341, Velcade), a potent TRAIL-sensitizing agent, increased sensitivity to IFN in two of the IFN-resistant cell lines that produced large amounts of TRAIL in response to IFN treatment. Our data show that IFN-induced apoptosis in bladder cancer cells frequently involves autocrine TRAIL production. Combination therapy strategies aimed at overcoming TRAIL resistance may be very effective in restoring IFN sensitivity in a subset of human bladder tumors.

This article has been cited by other articles:

				B. A. Hadaschik, K. Zhang, A. I. So, L. Fazli, W. Jia, J. C. Bell, M. E. Gleave, and P. S. Rennie Oncolytic Vesicular Stomatitis Viruses Are Potent Agents for Intravesical Treatment of High-Risk Bladder Cancer Cancer Res., June 15, 2008; 68(12): 4506 - 4510. [Abstract] [Full Text] [PDF]

				T. Yoshimoto, N. Morishima, I. Mizoguchi, M. Shimizu, H. Nagai, S. Oniki, M. Oka, C. Nishigori, and J. Mizuguchi Antiproliferative Activity of IL-27 on Melanoma J. Immunol., May 15, 2008; 180(10): 6527 - 6535. [Abstract] [Full Text] [PDF]

				J. Lechner, N. Malloth, T. Seppi, B. Beer, P. Jennings, and W. Pfaller IFN-{alpha} induces barrier destabilization and apoptosis in renal proximal tubular epithelium Am J Physiol Cell Physiol, January 1, 2008; 294(1): C153 - C160. [Abstract] [Full Text] [PDF]

				L. A. O'Brien, M. A. Richardson, S. F. Mehrbod, D. T. Berg, B. Gerlitz, A. Gupta, and B. W. Grinnell Activated Protein C Decreases Tumor Necrosis Factor Related Apoptosis-Inducing Ligand by an EPCR- Independent Mechanism Involving Egr-1/Erk-1/2 Activation Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2634 - 2641. [Abstract] [Full Text] [PDF]

				A. M. Kamat, G. Sethi, and B. B. Aggarwal Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-{kappa}B and nuclear factor-{kappa}B-regulated gene products in IFN-{alpha}-sensitive and IFN-{alpha}-resistant human bladder cancer cells Mol. Cancer Ther., March 1, 2007; 6(3): 1022 - 1030. [Abstract] [Full Text] [PDF]

				A. Papageorgiou, A. Kamat, W. F. Benedict, C. Dinney, and D. J. McConkey Combination therapy with IFN-{alpha} plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells Mol. Cancer Ther., December 1, 2006; 5(12): 3032 - 3041. [Abstract] [Full Text] [PDF]

				S. Khanbolooki, S. T. Nawrocki, T. Arumugam, R. Andtbacka, M. S. Pino, R. Kurzrock, C. D. Logsdon, J. L. Abbruzzese, and D. J. McConkey Nuclear factor-{kappa}B maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther., September 1, 2006; 5(9): 2251 - 2260. [Abstract] [Full Text] [PDF]

				J. Wu, X. Xiao, P. Zhao, G. Xue, Y. Zhu, X. Zhu, L. Zheng, Y. Zeng, and W. Huang Minicircle-IFN{gamma} Induces Antiproliferative and Antitumoral Effects in Human Nasopharyngeal Carcinoma Clin. Cancer Res., August 1, 2006; 12(15): 4702 - 4713. [Abstract] [Full Text] [PDF]

				T. J. Kemp, A. T. Ludwig, J. K. Earel, J. M. Moore, R. L. VanOosten, B. Moses, K. Leidal, W. M. Nauseef, and T. S. Griffith Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L Blood, November 15, 2005; 106(10): 3474 - 3482. [Abstract] [Full Text] [PDF]

				T. Minami, M. Adachi, R. Kawamura, Y. Zhang, Y. Shinomura, and K. Imai Sulindac Enhances the Proteasome Inhibitor Bortezomib-Mediated Oxidative Stress and Anticancer Activity Clin. Cancer Res., July 15, 2005; 11(14): 5248 - 5256. [Abstract] [Full Text] [PDF]